Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Health policy

Me-too drugs with limited benefits — the tale of regorafenib for HCC

Nature Reviews Clinical Oncology volume 14, pages 653–654 (2017)Cite this article

Subjects

An Erratum to this article was published on 28 November 2017

This article has been updated

Regorafenib is only the second agent approved by the FDA for the treatment of patients with advanced-stage hepatocellular carcinoma. Herein, we discuss the evidence that led to the approval of this agent. Examination of this process reveals important challenges associated with drug regulation, relating to trial design, treatment toxicity, and real-world clinical benefit.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 28 November 2017

    In the illustration that accompanies this article, the structures of regorafenib and sorafenib were incorrectly drawn. In both structures, a double bond was omitted from the central phenyl ring so that it appeared as a 1,3-cyclohexadiene. The figure has been corrected in both the HTML and PDF versions of this News & Views.

References

  1. U.S. Food and Drug Administration. FDA expands approved use of Stivarga to treat liver cancer. FDA https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm555608.htm (2017).

  2. National Cancer Institute at the National Institutes of Health. FDA approval for sorafenib tosylate. Cancer.gov https://www.cancer.gov/about-cancer/treatment/drugs/fda-sorafenib-tosylate (2013).

  3. Zhu, A. X. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11, 790–800 (2006).

    Article  CAS  PubMed  Google Scholar 

  4. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  PubMed  Google Scholar 

  5. Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).

    Article  CAS  PubMed  Google Scholar 

  6. Prasad, V., Massey, P. R. & Fojo, T. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J. Clin. Oncol. 32, 1620–1629 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sanoff, H. K., Chang, Y., Lund, J. L., O'Neil, B. H. & Dusetzina, S. B. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 21, 1113–1120 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Gyawali, B., Shimokata, T., Ando, M., Honda, K. & Ando, Y. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials. Ann. Oncol. 28, 246–253 (2017).

    CAS  PubMed  Google Scholar 

  9. Calcagno, F. et al. Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in French clinical practice. Clin. Med. Insights Oncol. 10, 59–66 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lee, I. C. et al. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore) 94, e688 (2015).

    Article  CAS  Google Scholar 

  11. He, A. R. & Goldenberg, A. S. Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap. Adv. Gastroenterol. 6, 447–458 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The work of V.P. is funded by the Laura and John Arnold Foundation to study low-value practices.

Author information

Authors and Affiliations

  1. Bishal Gyawali is at the Institute of Cancer Policy, King's College London, Guy's Hospital Campus, Great Maze Pond Road, London SE1 9RT, UK.,

    Bishal Gyawali

  2. Vinay Prasad is at the Division of Hematology Oncology in the Knight Cancer Institute; at the Department of Public Health and Preventive Medicine; and at the Center for Health Care Ethics Oregon at the Health and Sciences University, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA.,

    Vinay Prasad

  3. the Department of Public Health and Preventive Medicine,

    Vinay Prasad

Authors
  1. Bishal Gyawali
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vinay Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vinay Prasad.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gyawali, B., Prasad, V. Me-too drugs with limited benefits — the tale of regorafenib for HCC. Nat Rev Clin Oncol 14, 653–654 (2017). https://doi.org/10.1038/nrclinonc.2017.100

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2017.100

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research